Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obatoclax and Bortezomib in Relapsed or Refractory Mantle Cell Lymphoma
NCT00407303Phase 2Completed
- Sponsor
- Gemin X Pharmaceuticals
- Start
- Oct 2006
- Primary completion
- Mar 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of obatoclax in mantle cell lymphoma (MCL) (3 arms), sponsored by Gemin X Pharmaceuticals. Primary endpoints: Overall Response Rate and Safety Profile. Started Oct 2006; status: completed.
02
Drugs
obatoclax
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT00407303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00407303.